Other trials with octreotide for the prevention of postoperative complications
| Trial | Design | Groups | Total patients | High risk patients† n (%)) | Chronic pancreatitis (n (%)) | Mortality (n (%)) | Complication rate (n (%)) | Pancreatic fistulae (n (%)) |
|---|---|---|---|---|---|---|---|---|
| †High risk patients include non-fibrotic pancreatic tissue. | ||||||||
| ‡Surgery performed for presumed malignant disease revealed chronic pancreatitis. | ||||||||
| *p<0.07. | ||||||||
| ARC-AURC 199729 | Double blind, | Octreotide | 122 | 48 (39) | 12 (10) | 27 (22)* | 21 (17) | |
| multicentre | No treatment | 108 | 53 (49) | 27 | 35 (32) | 20 (18.5) | ||
| Lowy et al 199730 | Open, single | Octreotide | 57 | 56 (98) | 1 (2)‡ | 1 (2) | 17 (30) | 7 (12) |
| institution | No treatment | 53 | 49 (92) | 4 (8)‡ | 0 | 13 (25) | 3 (6) | |